About Anhui Anke Biotechnology Company

The company is a high-tech enterprise whose main business is biomedical R&D, production and sales, and was one of the first companies listed on the China GEM. The company's parent company is committed to the R&D, production and sales of genetically-engineered drugs and biological detection reagents. The subsidiary's business covers R&D, production and sales of modern proprietary Chinese medicines, chemically synthesized drugs, peptide drugs, forensic DNA testing, cellular drugs, etc. The company's main products currently include biological products, products of the parent company and products of the subsidiary Anke Huajie, modern proprietary Chinese medicines, products of the subsidiary Yu Liangqing Company, chemically synthesized drugs, products of the subsidiary Anke Hengyi Company, peptide drugs, and products of the subsidiary Soho Yiming. Corporate honors include the third prize of the National Science and Technology Progress Award, the first prize of the Anhui Science and Technology Progress Award, and the second prize of the Anhui Science and Technology Progress Award. It won the “2019 National Technological Innovation Demonstration Enterprise”, the “Outstanding Contribution Award - High Growth and Quality Award”, “2018 High-tech Zone Advanced Production Safety Unit”, “Quality Improvement and Efficiency Award - Production Safety Award”, “Innovation and Entrepreneurship Award - Harmonious Labor Relations Demonstration Enterprise Award”, “Technology Finance Award - Innovative Financing Award”, “Advanced Statistics Award”, and “2019 Hefei Gaoling New Enterprise Award””, 2022 The “Love Contribution Award” of the China Children and Adolescents Charitable Relief Foundation, the 25th Golden Bull Award for Listed Companies - “2022 Golden Letter Award”, etc.